Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279424 | 0.94 | PDE4A (0.44) | PDE4APDE4DPDE4BPDE4CS1PR1 | |
| SCHEMBL4274980 | 0.93 | PDE4A (0.43) | PDE4APDE4DPDE4BPDE4CS1PR1 | |
| SCHEMBL13701440 | 0.89 | CTNNB1 (0.45) | — | |
| SCHEMBL4277016 | 0.87 | S1PR1 (0.45) | PDE4APDE4DPDE4BPDE4CS1PR1 | |
| SCHEMBL4284472 | 0.86 | PDE4B (0.42) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL4276884 | 0.85 | EPHX2 (0.49) | PDE4APDE4DPDE4BPDE4CS1PR1 | |
| SCHEMBL4278417 | 0.85 | PDE4A (0.37) | PDE4APDE4DPDE4BPDE4CS1PR1 | |
| SCHEMBL4270743 | 0.84 | SMN1; SMN2 (0.45) | S1PR1S1PR3 | |
| SCHEMBL4281121 | 0.84 | S1PR1 (0.43) | PDE4APDE4DPDE4BPDE4CS1PR1 | |
| SCHEMBL4270719 | 0.84 | S1PR1 (0.44) | PDE4APDE4DPDE4BPDE4CS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICALC., LTD. (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| US-20220265613-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-08-25 | — | — | US | disclosed |
| US-20200078340-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-12 | — | — | US | disclosed |
| US-20190070151-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-03-07 | — | — | US | disclosed |
| US-RE46792-E1 | Oxazole compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-04-17 | — | — | US | disclosed |
| US-20170216260-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-1954684-B1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20140100226-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-04-10 | — | — | US | disclosed |
| US-8637559-B2 | Oxazole compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20090221586-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-09-03 | — | — | US | disclosed |
| EP-1954684-A2 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007058338-A9 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007058338-A2 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216260-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | PDE4A 2/4885PDE4D 11/4885PDE4B 5/4885 |
| US-20140100226-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | PDE4A 2/4885PDE4D 11/4885PDE4B 5/4885 |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | PDE4A 2/4885PDE4D 11/4885PDE4B 5/4885 |
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE7B, PDE4B, PDE1B | PDE4A 10/4885PDE4D 8/4885PDE4B 2/4885 |
| US-20090221586-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | PDE4A 2/4885PDE4D 11/4885PDE4B 5/4885 |
| US-20200078340-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | PDE4A 2/4885PDE4D 11/4885PDE4B 5/4885 |
| US-20220265613-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | PDE4A 2/4885PDE4D 11/4885PDE4B 4/4885 |
| US-20190070151-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | PDE4A 2/4885PDE4D 11/4885PDE4B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.